FDA lifts hold for AZ's durvalumab in head and neck cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA lifted a partial clinical hold on enrollment of patients with squamous cell carcinoma of

Read the full 205 word article

User Sign In